UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K					
		T	TA //	n	T
	н	JК	IVI.	X-	n

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2019

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation)
255 State Street, 9th Floor Boston, MA
(Address of principal executive offices)

001-37471 (Commission File Number) 30-0784346 (IRS Employer Identification No.)

> 02109 (Zip Code)

Registrant's telephone number, including area code: 857-246-8998

 $$N\!/\!A$$ (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 $\begin{tabular}{ll} \Box & Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \\ \hline \end{tabular}$

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company $\ oxtimes$

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for con Exchange Act. \Box	nplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Item 7.01: Regulation FD Disclosure.

On May 22, 2019, Pieris Pharmaceuticals, Inc. presented clinical data related to its phase 1a study of PRS-060 at the American Thoracic Society 2019 International Conference. The poster is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.1 attached hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing. except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Conference Poster, Dated May 22, 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: May 22, 2019 /s/ Allan Reine

Allan Reine

Chief Financial Officer

First-in-human data for the inhaled IL-4Rα antagonist AZD1402/PRS-060 reveals a promising clinical profile for the treatment of asthma


Bruns IB,¹Fitzgerald MF,¹Pardali K,² Gardiner P,³Keeling DJ,²Axelsson LT,²Jiang F,²Lickliter J,⁴Close DR⁵

'Pleris Pharmaceuticals, Boston, MA, USA; 'Early Respiratory, Inflammation and Autoimmunity, R&D Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden; 'Clinical Pharmacology and Safety Sciences, R&D Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden; 'Nucleus Network, Melbourne, Australia; 'Early Respiratory, Inflammation and Autoimmunity, R&D Biopharmaceuticals, AstraZeneca, Cambridge, UK






- AZD1402PRS-060 or matching placebo estministered using an in-s Healthcans, Ametandom, Netherlands) or introvensually, thy men or women of non-childbearing potential between 18 and






complications			
Muscle injury	1 (6) 1	0	1.00%
Note: In, Survivor of screens, is number of autopota in the	specified category. Notice to	discoveraged above	SHIELD THE SHIP








- standard deviation (90%) righted from 4.2 (1.7) hours in cohort 4 notice? $(950 \, \mathrm{mg})$ (Table 9), the mean (90%) $_0$ see 2.2 (0.8) hours for cohort 5 and 2.3 (0.1) hours



pie

Astra



oferences Lippo HO et al. Thoras 2012 87761-98. Institute G et al. / Die filler 2006 2001 1436-98. Institute G et al. / Die filler 2006 2001 1436-98. Institute G et al. / Die filler 2006 2001 1436-98.	1	:	Wasser Street Dager Pilled at
knowledgments and an executive from the natural states of the securities and the securities are securities are securities are securities and the securities are secu		nd by Asim/James Mark UR.	a, Pilolini wito